Premium
Second‐Generation Iminoxylitol‐Based Pharmacological Chaperones for the Treatment of Gaucher Disease
Author(s) -
Oulaïdi Farah,
FrontDeschamps Sophie,
Gallienne Estelle,
Lesellier Eric,
Ikeda Kyoko,
Asano Naoki,
Compain Philippe,
Martin Olivier R.
Publication year - 2011
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201000469
Subject(s) - stereocenter , alkyl , glucocerebrosidase , stereochemistry , chaperone (clinical) , chemistry , pharmacology , biology , biochemistry , enzyme , medicine , organic chemistry , pathology , enantioselective synthesis , catalysis
A series of O ‐alkyl iminoxylitol derivatives was synthesized and evaluated as β‐glucocerebrosidase (GCase) inhibitors. This structure–activity study shows a dramatic influence of the position of the alkyl chain (α‐C1, O2, O3, or O4) on human GCase inhibition. Remarkably, 1,2‐shift of the alkyl chain from C1 to O2 was found to maintain high inhibitory potency toward GCase as well as chaperone activity at sub‐inhibitory concentration (10 n M ). Removal of the stereogenic center at the pseudo‐anomeric position led to shorter and more practical synthetic sequences. 2‐ O ‐Alkyl iminoxylitol derivatives constitute a new promising class of leads for the treatment of Gaucher disease by means of pharmacological chaperone therapy.